Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 5 January 2026 - 6 January 2026

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly shares rose about 1.6% Tuesday after Nimbus Therapeutics announced a deal to develop an oral obesity drug with the company. Nimbus will receive $55 million upfront and could get up to $1.3 billion in total payments plus royalties. The agreement follows Novo Nordisk’s U.S. launch of its $149-a-month Wegovy pill, intensifying focus on oral weight-loss treatments.
6 January 2026
··
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

Alumis shares surged 129% Tuesday after its psoriasis pill, envudeucitinib, met all main goals in Phase 3 trials. About 65% of patients reached PASI 90 and over 40% achieved complete clearance at week 24. The company reported no new safety concerns and plans to file for FDA approval in the second half of 2026. Traders are watching durability and safety data.
6 January 2026
··
AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

Health Canada approved AbbVie’s Maviret for acute and chronic hepatitis C in adults and children aged 3 and older. AbbVie shares were flat premarket at $220.18 after falling nearly 4% Monday. The approval followed a Priority Review based on Phase 3 data. Investors await AbbVie’s Jan. 14 appearance at the J.P. Morgan Healthcare Conference.
6 January 2026
··
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly shares fell 3.6% to $1,041.51 in after-hours trading Monday after Novo Nordisk launched a pill version of its Wegovy weight-loss drug in the U.S. Novo’s shares rose 5.2% as investors reacted to new pricing and distribution details. Lilly’s stock traded as low as $1,034 earlier in the session. Investors await commentary at the J.P. Morgan Healthcare Conference and Lilly’s earnings call.
6 January 2026
···
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

Xenon Pharmaceuticals shares fell 6.5% to $41.60 Monday afternoon, underperforming biotech peers ahead of next week’s J.P. Morgan Healthcare Conference. The stock traded between $45.21 and $41.45 on volume of 787,000 shares. Cantor Fitzgerald raised its price target to $55 despite the drop. Investors await updates on late-stage epilepsy trial timelines and commercialization plans.
5 January 2026
··
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Brand Engagement Network (BNAI) stock rises again premarket as AI pharma deal keeps traders hooked

Brand Engagement Network (BNAI) stock rises again premarket as AI pharma deal keeps traders hooked

Brand Engagement Network shares rose 5.3% to $3.97 in premarket trading Monday, extending Friday’s 62.5% surge. The rally follows disclosure of a $250,000 AI services deal for a top pharmaceutical client. Investors are watching for sustained volume and updates on project timing. The company reported $60,120 in quarterly revenue and $102,715 in cash as of Sept. 30.
5 January 2026
···
Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals shares rose about 1% premarket Monday after Citizens upgraded the stock, citing eased pricing pressure on Linzess. The company last week cut Linzess’s list price by about 50% and forecast 2026 revenue of $450–$475 million. Shares closed up 26.7% Friday at $4.27, with trading volume surging to 85 million. Ironwood remains in a strategic alternatives review and plans a Phase 3 apraglutide trial in 2026.
5 January 2026
··
1 … 17 18 19 20 21 … 38

Stock Market Today

  • XRP Rises as Japan Classifies Token as Financial Asset, Boosting Market Sentiment
    April 11, 2026, 11:29 AM EDT. Ripple's XRP gained to $1.35 after Japan's cabinet approved a bill classifying the token as a financial instrument under the Financial Instruments and Exchange Act. This regulatory clarity, set to take effect in fiscal 2027, reduces legal uncertainty for Japanese banks-over 80% of which connect with Ripple's network-and fuels investor optimism. XRP's market cap stood at $82.6 billion with a 26% drop in trading volume to $1.77 billion over 24 hours. Positive sentiment is also driven by potential U.S. regulatory progress with the CLARITY Act, expected in late April, which could facilitate inflows into crypto ETFs. Technical analysts point to cautious bullish momentum, with short-term trading between $1.30 and $1.40, and longer-term targets suggesting substantial upside. These developments position XRP for stronger institutional use and growth in cross-border payments.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 11:42 AM EDT XRP Rises as Japan Classifies Token as Financial Asset, Boosting Market Sentiment April 11, 2026, 11:29 AM EDT. Ripple's XRP gained to $1.35 after Japan's cabinet approved a bill classifying the token as a financial instrument under the Financial Instruments and Exchange Act. This regulatory clarity, set to take effect in fiscal 2027, reduces legal uncertainty for Japanese banks-over 80% of which connect with Ripple's network-and fuels investor optimism. XRP's market cap stood at $82.6 billion with a 26% drop in trading volume to $1.77
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop